India Drops MNC Negotiation Plans Without New Drug Price Controls
This article was originally published in PharmAsia News
India's delay in adopting a new drug price control plan has had a fallout effect on other plans to reduce the cost of imported drugs and medical devices. The government had planned to conduct negotiations with multinational drug makers, but canceled them when several ministries involved could not reach agreement on a new price control plan April 30. That failure was attributed to the Health Ministry, the same ministry that had planned to negotiate with the MNCs. (Click here for more
You may also be interested in...
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.
Hikma has pushed back against a further attempt by Amarin to counter its US generic version of Vascepa, this time via a fresh lawsuit claiming that the generic induces infringement of patents protecting cardiovascular indications for which the brand is approved but which are carved out of the generic label.
The European Medicines Agency will continue working over the Christmas period so that it can complete its assessment of the newly filed marketing applications for BioNTech/Pfizer’s and Moderna’s COVID-19 vaccines as soon possible.